Dengue fever

Authors: M. Trojánek 1;  V. Marešová 1;  F. Stejskal 1,2,3
Authors‘ workplace: I. infekční klinika, 2. LF UK v Praze a Nemocnice Na Bulovce, Praha Přednosta: doc. MUDr. Dušan Pícha, CSc. 1;  Infekční oddělení, Krajská nemocnice Liberec Primář: MUDr. Adam Vitouš 2;  Ústav imunologie a mikrobiologie, 1. LF UK v Praze a VFN, Praha Přednostka: prof. RNDr. Libuše Kolářová, CSc. 3
Published in: Prakt. Lék. 2013; 93(4): 163-168
Category: Various Specialization


Dengue fever is considered to be the most widely spread arthropod-borne viral disease, which is present in many tropical and subtropical regions. Infection is produced by any of four closely related serotypes of dengue RNA virus, which belongs to the family Flaviviridae. The principal vectors of dengue are Aedes aegypti mosquitoes. Dengue represents one of the most frequently imported febrile tropical infections to developed countries from South and Southeast Asia and Latin America. The infestation with Aedes albopictus mosquitoes is considered as significant risk for the disease spread to new non-endemic regions. These mosquitoes are present even in southern Europe, where cases of autochthonous transmission have recently been described. Infection may be asymptomatic or presents as classical dengue fever or may lead to dengue haemorrhagic fever and shock syndrome. Severe infections are seen more frequently in young children and are usually associated with secondary infection with a different dengue serotype. Dengue has an incubation period of around 4 to 7 days. Typical symptoms are fever, arthralgia, myalgia, headache and maculopapular rash. Laboratory findings include leukocytopenia, thrombocytopenia and elevation of aminotransferases. Diagnosis can be confirmed by ELISA detection of IgM and IgG antibodies, however, recently methods of direct detection have been introduced such as detection of viral RNA or NS1 antigen, which are usually positive in the early febrile phase of dengue. There is no specific treatment available, future vaccines are intended for use especially for children living in the endemic areas.

dengue – tropical medicine – imported infections – fever


1. Rigau-Perez JG, Clark GG, Gubler DJ, et al. Dengue and dengue haemorrhagic fever. Lancet 1998; 352(9132): 971–977.

2. Oishi K, Saito M, Mapua CA, et al. Dengue illness: clinical features and pathogenesis. J Infect Chemother 2007; 13(3): 125–133.

3. Ooi EE, Dubler GD. Dengue and dengue hemorrhagic fever. In Guerrant RL, et al. Tropical Infectious Diseases. 3rd Ed. Edinburgh: Elsevier 2011; 504–510.

4. McBride WJ, Bielefeldt-Ohmann H. Dengue viral infections; pathogenesis and epidemiology. Microbes Infect 2000; 2(9): 1041–1050.

5. Ryan ET, Wilson ME, Kain KC. Illness after international travel. N Engl J Med 2002; 347(7): 505–516.

6. Gould EA, Gallian P, De Lamallerie X, et al. First cases of autochthonous dengue fever and chikungunya fever in France: from bad dream to reality! Clin Microbiol Infect 2010; 16(12): 1702–1704.

7. Halstead SB. Dengue. London: Imperial College Press 2008: 29–83. Ser. Tropical Medicine: Science and Practice. Vol. V. ISBN 10- 1-84816-228-6.

8. Chen Y, Maguire T, Marks RM. Demonstration of binding of dengue virus envelope protein to target cells. J Virol 1996; 70(12): 8765–8772.

9. Lai CY, Tsai WY, Lin SR, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 2008; 82(13): 6631–6643.

10. Basu A, Chaturvedi UC. Vascular endothelium: the battlefield of dengue viruses. FEMS Immunol Med Microbiol, 2008; 53(3): 287–299.

11. Wang E, Ni H, Xu R, et al. Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J Virol 2000; 74(7): 3227–3234.

12. Gubler DJ, Rosen L. Variation among geographic strains of Aedes albopictus in susceptibility to infection with dengue viruses. Am J Trop Med Hyg 1976; 25(2): 318–325.

13. Rudnick A. Ecology of dengue viruses. Asian J Infect Dis 1978; 2: 156–160.

14. Diallo M, Ba Y, Sall AA, et al. Amplification of the sylvatic cycle of dengue virus type 2, Senegal, 1999-2000: entomologic findings and epidemiologic considerations. Emerg Infect Dis 2003; 9(3): 362–367.

15. Kuno G. Research on dengue and dengue-like illness in East Asia and the Western Pacific during the first half of the 20th century. Rev Med Virol 2007; 17(5): 327–341.

16. Guzman A, Isturiz RE. Update on the global spread of dengue. Int J Antimicrob Agents 2010; 36(Suppl 1): S40–42.

17. Bulugahapitiya U, Siyambalapitiya S, Seneviratne SL, et al. Dengue fever in travellers: a challenge for European physicians. Eur J Intern Med 2007; 18(3): 185–192.

18. Huhtamo E, Vuorinen S, Uzcategui NY, et al. Fatal dengue virus infection in a Finnish traveler. J Clin Virol 2006; 37(4): 323–326.

19. Schmidt-Chanasit J, Tenner-Racz K, Poppert D, et al. Fatal dengue hemorrhagic fever imported into Germany. Infection 2012; 40(4): 441–443.

20. Vainio K, Noraas S, Holmberg M, et al. Fatal and mild primary dengue virus infections imported to Norway from Africa and south-east Asia, 2008-2010. Euro Surveill 2010; 15(38): 1–4.

21. Wu SJ. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 2000; 6(7): 816–820.

22. Murgue B. Severe dengue: questioning the paradigm. Microbes Infect 2010; 12(2): 113–118.

23. Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine 2011; 29(42): 7221–7228.

24. Hammon WM, Rudnick A, Sather GE. Viruses associated with epidemic hemorrhagic fevers of the Philippines and Thailand. Science 1960; 131(3407): 1102–1103.

25. Murrell S, Wu SC, Butler M. Review of dengue virus and the development of a vaccine. Biotechnol Adv. 2011; 29(2): 239–247.

26. Wichmann O, Mühlberger N, Jelinek T. Dengue-the underestimated risk in travellers. Dengue Bull 2003; 27: 126–137.

27. Kurane I, Takasaki T. Dengue fever and dengue haemorrhagic fever: challenges of controlling an enemy still at large. Rev Med Virol 2001; 11(5): 301–311.

28. Hayes EB, Gubler DJ. Dengue and dengue hemorrhagic fever. Pediatr Infect Dis J 1992; 11(4): 311–317.

29. Wichmann O, Jelinek T. Dengue in travelers: a review. J Travel Med 2004; 11(3): 161–170.

30. Gibbons, R. V., Vaughn, D. W. Dengue: an escalating problem. BMJ, 2002, 324(7353): 1563–1566.

31. Deen JL, Harris E, Wills B, et al. The WHO dengue classification and case definitions: time for a reassessment. Lancet 2006; 368(9530): 170–173.

32. Gulati S, Maheshwari A. Atypical manifestations of dengue. Trop Med Int Health 2007; 12(9): 1087–1095.

33. Teles FR, Prazeres DM, Lima-Filho JL. Trends in dengue diagnosis. Rev Med Virol 2005; 15(5): 287–302.

34. Wichmann O, Stark K, Shu PY, et al. Clinical features and pitfalls in the laboratory diagnosis of dengue in travellers. BMC Infect Dis 2006; 6: 120.

35. Halstead SB. Dengue. Lancet 2007; 370(9599): 1644–1652.

36. Dung NM, Day NP, Tam DT, et al. Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens. Clin Infect Dis 1999; 29(4): 787–794.

37. Schmitz J, Roehrig J, Barrett A, et al. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 2011; 29(42): 7276–7284

General practitioner for children and adolescents General practitioner for adults
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account